Replies to Post #69385 onSavvy Trades and Investments

Play Episode

3min

Proactive - Interviews for investors

Caledonia Mining CEO talks record Q1 & solar sale

Caledonia Mining Corporation PLC chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about a record first quarter for gold production at the company's Blanket Mine. Learmonth attributed the strong operational performance to significant management changes and the restructuring of the mine's operations, which split underground and surface responsibilities. “We've got a new, younger, more energetic management team underground... and it's worked beautifully,” Learmonth noted, highlighting the benefits of recent personnel shifts and structural reforms. The conversation also covered the recent $22.35 million sale of Caledonia’s solar power plant in Zimbabwe. While the asset has been sold, Learmonth said the company retains a long-term power supply agreement and the option to participate in a second phase, if viable. He clarified the decision allows Caledonia to concentrate more on its core gold mining business. Looking ahead, Learmonth said the company remains focused on maximising gold production while intensifying efforts to reduce long-term costs. “At this gold price, with production strong, we want to get that gold out the ground... with increasing attention now to more management focus on getting those costs down,” he said. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #CaledoniaMining #GoldProduction #BlanketMine #ZimbabweMining #MarkLearmonth #MiningNews #SolarEnergy #EnergyResilience #GoldMining #ProactiveInvestors

Proactive - Interviews for investors

European Green Transition co-founder Cathal Friel outlines growth strategy as he takes chair

European Green Transition PLC (AIM:EGT) founder and non-executive chairman Cathal Friel talked with Proactive's Stephen Gunnion about his formal move into the non-executive chairman role and the company’s strategy going forward. Friel shared how European Green Transition (EGT) aims to build value by acquiring distressed yet revenue-generating assets, a model he has successfully applied with previous companies such as Amryt Pharma and hVIVO. “Our model going forward is to acquire low-priced, distressed, good value assets, bolt them together,” he said, emphasising the need for revenue-generating components or the capacity to make acquisitions profitable from day one. He reflected on EGT’s IPO in April 2024 and his transition from other responsibilities, including his long tenure with hVIVO. With that chapter closed, he now brings more focus to EGT’s growth. Friel confirmed that the company still holds the majority of the £6.5 million raised, having only used a small portion on its rare earth asset in Sweden. Monetising that asset remains a priority. EGT's strategy continues to centre on small teams, tight cost control, and targeting multi-fold returns over a 24-month horizon. “I’ll be very careful of [the shareholders’] cash. It’s like mine,” Friel added. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #CathalFriel #EuropeanGreenTransition #EGT #RareEarths #MergersAndAcquisitions #SmallCapInvesting #GreenEconomy #MiningInvestment #ShareholderValue #hVIVO #AmrytPharma #IPO

Proactive - Interviews for investors

IXICO CEO on H1 trading update and revenue drivers in Alzheimer’s trials

IXICO plc CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strategy for innovation, leadership, and growth in the neurodegenerative disease space. Goorden outlined how IXICO’s precision medicine platform, TTNx, uses AI to analyse imaging data for pharmaceutical and biotech companies developing new drugs, particularly in Alzheimer’s, Parkinson’s, and Huntington’s diseases. The CEO emphasised that the company's focus remains on expanding its portfolio, enhancing analytics within existing programs, and tapping into emerging opportunities like blood-based biomarkers. “You may know that IXICO is an absolute leader in especially rare diseases, Huntington's disease and so on, but we've really seen that expansion of portfolio,” Goorden said. He also discussed the company’s strategic pillars: Innovate, Lead, and Scale. This includes integrating new algorithms, raising the company’s voice in the global precision medicine market, and strengthening its US operations to support further growth. Goorden noted that IXICO is seeing increased engagement from partners seeking FDA approvals who rely on gold-standard imaging for validation. He also mentioned the company’s recent hires and commitment to driving more partnerships throughout 2025. Visit Proactive’s YouTube channel for more exclusive interviews and insights. Don’t forget to like this video, subscribe to our channel, and turn on notifications for future updates. #IXICO #BramGoorden #PrecisionMedicine #NeurodegenerativeDiseases #AlzheimersResearch #ParkinsonsDisease #DrugDevelopment #AIinHealthcare #Biomarkers #ClinicalTrials #HealthcareInnovation #FDAapproval

Proactive - Interviews for investors

Scancell fast-tracks melanoma study with NHS

Scancell Holdings PLC CEO Phillip L’Huillier joined Proactive's Stephen Gunnion with details of the company’s partnership with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study evaluating the iSCIB1+ DNA cancer vaccine. L’Huillier described the deal as “a very positive endorsement for Scancell and for the medicines that we are developing,” noting that the therapy is showing promise in delivering long-term immune control in advanced melanoma patients. The NHS collaboration enables hospitals to more quickly access and offer the iSCIB1+ therapy as part of the trial, making Scancell the first UK company to partner with the platform and the first to offer a DNA cancer vaccine through it. He explained that the vaccine is given alongside checkpoint inhibitors, currently standard care, to boost response rates and prolong efficacy, especially where standard therapy alone sees limited, short-lived results. L’Huillier confirmed multiple SCOPE study data readouts are expected in 2025, with a larger development phase targeted for 2026. The company is also progressing its Modi-1 peptide vaccine and aims to further develop its GlyMab antibody platform, including the SC134 programme for small cell lung cancer. L’Huillier said his CEO priorities include sticking to development timelines, building strategic partnerships, and preparing the organisation for future phases. For more exclusive biotech interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future updates. #Scancell #CancerVaccine #BiotechNews #iSCIB1 #MelanomaResearch #NHSPartnership #DNAImmunotherapy #Modi1 #ClinicalTrials #OncologyInnovation #InvestorUpdate #ProactiveInvestors

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free